Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGENNYSE:EBSNASDAQ:MYGNNASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$3.82+0.8%$2.44$1.38▼$19.69$104.73M1.48591,358 shs422,744 shsEBSEmergent BioSolutions$6.40-1.5%$5.24$4.02▼$15.10$347.38M2.091.85 million shs1.18 million shsMYGNMyriad Genetics$3.91-0.5%$7.15$3.81▼$29.30$360.41M2.011.14 million shs1.61 million shsRIGLRigel Pharmaceuticals$18.95-4.0%$18.42$7.48▼$29.82$338.67M1.34217,173 shs269,431 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus+0.79%+9.77%+34.04%+15.06%-67.93%EBSEmergent BioSolutions-1.08%-3.83%+28.39%-17.32%+27.49%MYGNMyriad Genetics-0.51%-5.33%-46.36%-72.45%-83.70%RIGLRigel Pharmaceuticals-3.95%-4.44%+4.35%-5.67%+105.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus3.9535 of 5 stars3.12.00.04.63.81.70.6EBSEmergent BioSolutions4.4028 of 5 stars3.53.00.04.62.42.51.3MYGNMyriad Genetics4.0002 of 5 stars4.02.00.04.11.71.70.6RIGLRigel Pharmaceuticals2.9473 of 5 stars3.22.00.00.03.61.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.17Hold$9.00135.60% UpsideEBSEmergent BioSolutions 3.00Buy$14.33123.96% UpsideMYGNMyriad Genetics 2.06Hold$14.79278.15% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.4092.08% UpsideCurrent Analyst Ratings BreakdownLatest AGEN, MYGN, EBS, and RIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025MYGNMyriad GeneticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.005/15/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.005/13/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/13/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.005/8/2025MYGNMyriad GeneticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform5/7/2025MYGNMyriad GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$18.005/7/2025MYGNMyriad GeneticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/7/2025MYGNMyriad GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.005/7/2025MYGNMyriad GeneticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $7.005/7/2025MYGNMyriad GeneticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$22.00 ➝ $6.005/7/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$99.52M1.05N/AN/A($7.78) per share-0.49EBSEmergent BioSolutions$930.30M0.37$0.72 per share8.92$12.51 per share0.51MYGNMyriad Genetics$831.30M0.43N/AN/A$9.53 per share0.41RIGLRigel Pharmaceuticals$203.08M1.67N/AN/A($1.64) per share-11.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$245.76M-$8.67N/AN/AN/A-145.89%N/A-85.68%N/AEBSEmergent BioSolutions-$760.50M-$2.71N/A3.09N/A-18.55%-9.91%-3.31%8/5/2025 (Estimated)MYGNMyriad Genetics-$263.30M-$1.12N/AN/AN/A-14.09%-4.51%-3.07%8/5/2025 (Estimated)RIGLRigel Pharmaceuticals-$25.09M$2.07135.3718.05N/A2.46%-14.80%3.03%8/5/2025 (Estimated)Latest AGEN, MYGN, EBS, and RIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AGENAgenus-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million5/7/2025Q1 2025EBSEmergent BioSolutions$0.49$0.71+$0.22$1.19$218.50 million$222.20 million5/6/2025Q1 2025MYGNMyriad Genetics-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14$0.63+$0.49$0.63$43.87 million$53.33 million3/11/2025Q4 2024AGENAgenus-$2.36-$2.04+$0.32-$2.04$30.09 million$26.84 million3/4/2025Q4 2024RIGLRigel Pharmaceuticals$0.30$0.80+$0.50$0.80$57.59 million$57.60 million3/3/2025Q4 2024EBSEmergent BioSolutions-$0.35$0.05+$0.40-$0.58$254.67 million$194.70 million2/25/2025Q4 2024MYGNMyriad Genetics$0.03-$0.09-$0.12-$0.47$210.35 million$210.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/AEBSEmergent BioSolutionsN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.190.19EBSEmergent BioSolutions1.302.881.47MYGNMyriad Genetics0.051.901.73RIGLRigel PharmaceuticalsN/A1.961.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%EBSEmergent BioSolutions78.40%MYGNMyriad Genetics99.02%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%EBSEmergent BioSolutions3.20%MYGNMyriad Genetics2.10%RIGLRigel Pharmaceuticals9.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44027.42 million22.38 millionOptionableEBSEmergent BioSolutions2,42054.28 million53.53 millionOptionableMYGNMyriad Genetics2,60092.18 million89.12 millionOptionableRIGLRigel Pharmaceuticals16017.87 million16.02 millionOptionableAGEN, MYGN, EBS, and RIGL HeadlinesRecent News About These CompaniesJane Street Group LLC Has $1.05 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)May 24 at 3:19 AM | marketbeat.comRigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 CongressMay 22 at 5:20 PM | prnewswire.comSoleus Capital Management L.P. Boosts Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)May 21 at 8:07 AM | marketbeat.com17,123 Shares in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Acquired by Dimensional Fund Advisors LPMay 20, 2025 | marketbeat.comEnsign Peak Advisors Inc Makes New $1.44 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)May 19, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Stock Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)May 17, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCMay 16, 2025 | marketbeat.comHere's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock NowMay 14, 2025 | zacks.comIs Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?May 13, 2025 | zacks.comUpgrade: Analysts Just Made A Captivating Increase To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) ForecastsMay 11, 2025 | finance.yahoo.comB. Riley Expects Reduced Earnings for Rigel PharmaceuticalsMay 11, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of RIGL Q2 EarningsMay 11, 2025 | marketbeat.comB. Riley Equities Analysts Lift Earnings Estimates for RIGLMay 10, 2025 | marketbeat.comEquities Analysts Offer Predictions for RIGL Q3 EarningsMay 10, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Hold" by AnalystsMay 10, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. Just Recorded A 370% EPS Beat: Here's What Analysts Are Forecasting NextMay 9, 2025 | uk.finance.yahoo.comEarnings Estimates Rising for Rigel (RIGL): Will It Gain?May 9, 2025 | zacks.comRigel Pharmaceuticals (NASDAQ:RIGL) Price Target Raised to $23.00May 9, 2025 | marketbeat.comWall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a BetMay 8, 2025 | zacks.comRigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | finanznachrichten.deWhy Rigel Pharmaceuticals, Inc.’s (RIGL) Stock Is Up 27.08%May 8, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumDoorDash’s Uptrend Is Gaining Momentum in 2025By Thomas Hughes | May 9, 2025View DoorDash’s Uptrend Is Gaining Momentum in 2025IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthBy Jeffrey Neal Johnson | May 8, 2025View IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthAGEN, MYGN, EBS, and RIGL Company DescriptionsAgenus NASDAQ:AGEN$3.82 +0.03 (+0.79%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.83 +0.01 (+0.26%) As of 05/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Emergent BioSolutions NYSE:EBS$6.40 -0.10 (-1.54%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$6.41 +0.01 (+0.16%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Myriad Genetics NASDAQ:MYGN$3.91 -0.02 (-0.51%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.98 +0.07 (+1.79%) As of 05/23/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Rigel Pharmaceuticals NASDAQ:RIGL$18.95 -0.78 (-3.95%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$18.80 -0.15 (-0.77%) As of 05/23/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
